BRAF

Oncology

17 drugs in development·10 companies·1 clinical trial

Drug Pipeline by Phase

Approved(4)

Drug	Company
braftovi	ARRAY BIOPHARMA INC (ARRY)
mekinist	Novartis AG (NVS)
mektovi	ARRAY BIOPHARMA INC (ARRY)
ojemda	Day One Biopharmaceuticals, Inc. (DAWN)

Phase 3(2)

Drug	Company
Amivantamab + FOLFIRI	IGM Biosciences, Inc. (IGMS)
Encorafenib	IGM Biosciences, Inc. (IGMS)

Phase 2(3)

Drug	Company
Amivantamab	IGM Biosciences, Inc. (IGMS)
Amivantamab IV	IGM Biosciences, Inc. (IGMS)
Iparomlimab and Tuvonralimab	IGM Biosciences, Inc. (IGMS)

Phase 1(3)

Drug	Company
BDTX-4933	Black Diamond Therapeutics, Inc. (BDTX)
BET Bromodomain Inhibitor ZEN-3694	Amneal Pharmaceuticals, Inc. (AMRX)
Encorafenib	ENANTA PHARMACEUTICALS INC (ENTA)

Preclinical(2)

Drug	Company
Pan-mutant BRAF degrader program (proprietary)	Nurix Therapeutics, Inc. (NRIX)
Pan-mutant BRAF program (mutant BRAF degraders)	Nurix Therapeutics, Inc. (NRIX)

Unknown(1)

Drug	Company
tafinlar/mekinist	Novartis AG (NVS)

Phase 1/Phase 2(2)

Drug	Company
brimarafenib	SpringWorks Therapeutics, Inc. (SWTX)
eli-007	Elicio Therapeutics, Inc. (ELTX)

BioSniper tracks 17 drugs in development for BRAF across 10 companies.

There are 1 clinical trial targeting BRAF tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.